Cord blood stem cells tested in stroke patients – early safety check

NCT ID NCT03186456

Terminated Disease control Sponsor: Sclnow Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether stem cells from donated umbilical cords are safe for people who recently had a stroke. Forty participants will receive three monthly infusions of the cells along with standard aspirin therapy. The study is currently on hold, and its main goal is to monitor for side effects, not to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human umbilical cord-derived mesenchymal stem cells
What this could lead to: If it works, this could point toward a new way to help people recover from stroke by reducing brain damage.
What could go wrong: This is a very early, small trial (Phase 1, 40 people) that is currently suspended. It only tests safety, not whether it truly works, and stem cell treatments carry risks like infection or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CEREBRAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CEREBRAL INFARCTION

Contacts and locations

Locations

Inner Mongolia International Mongolian Hospital

Hohhot, Inner Mongolia, 010065, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.